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Research
Arsenic exposure is a well-recognized public 
health problem: Millions of people world-
wide are potentially exposed predominantly 
to inorganic arsenic from drinking water 
contaminated by naturally occurring sources 
(Tchounwou et al. 1999). Chronic exposure to 
arsenic is associated with a number of adverse 
health effects (Yoshida et al. 2004). 
Accumulating evidence from epidemio-
logic and experimental studies has shown an 
increased risk of type 2 diabetes in populations 
with high exposure to arsenic (Longnecker 
and Daniels 2001; Navas-Acien et al. 2006; 
Tseng et al. 2002). One recent study found 
an association between arsenic exposure and 
diabetes in a nationally representative sam-
ple of U.S. adults (Navas-Acien et al. 2008). 
Arsenic-induced diabetes may occur through 
induction of insulin resistance and beta-cell 
dysfunction by arsenic (or its methylated 
metabolites) via induction of oxidative stress 
or interferences in signal transduction or gene 
expression (Tseng 2004). Individual factors 
(e.g., nutritional status, genes) may also influ-
ence arsenic toxicity (Vahter 2007). 
Few studies have explored the effects 
of arsenic on human pregnancy outcomes 
(Huyck et al. 2007; Rahman et al. 2007; 
Vahter et al. 2006), and none have investi-
gated risk of diabetes in pregnant women, 
even though diabetes is a major potential 
complication of pregnancy with adverse effects 
for both mothers and infants. Gestational dia-
betes (GD) occurs when resistance to circulat-
ing insulin leads to hyperglycemia, and this 
impaired glucose metabolism is first detected 
during pregnancy. GD has an estimated prev-
alence of 1–14% of all pregnancies depending 
on race/ethnicity and diagnostic criteria used 
[American Diabetes Association (ADA) 2004; 
Ferrara 2007]. Although there is some con-
troversy over the definitive screening crite-
ria, GD is usually first identified by testing a 
women’s blood glucose level 1 hr after receiv-
ing a 50-g oral glucose challenge between 
24 and 28 weeks gestation as part of routine 
prenatal care [American College of Obstetrics 
and Gynecology (ACOG) 2001]. 
GD is associated with 30–60% increased 
risk of developing diabetes in later life in 
the mother and also poses intergenerational 
risks to the fetus (Metzger 2007). Diabetes in 
pregnancy is associated with increased risk of 
major congenital malformations, macrosomia 
(birth weight > 4,000 g or > 90th percentile 
for gestational age), and complications during 
delivery and in the perinatal period including 
stillbirth (Fetita et al. 2006). Infants born to 
mothers with impaired glucose tolerance/GD 
are at increased risk of subsequent impaired 
glucose tolerance and obesity. However, there 
is evidence that early intervention and treat-
ment, such as dietary counseling, blood glu-
cose monitoring, and insulin or other drugs 
(if appropriate), may lead to improved out-
comes for mother and child (World Health 
Organization 2006). Therefore, it is an 
important public heath priority to identify 
risk factors for GD.
We examined maternal arsenic exposure 
and risk of impaired glucose tolerance during 
pregnancy, which is an important determinant 
of GD, in a population of pregnant women 
living in an area surrounding the Tar Creek 
Superfund site in Ottawa County, Oklahoma.
Materials and Methods
Study location. The Tar Creek Superfund 
site, a former lead and zinc mining area, 
occupies 40 square miles of land in north-
eastern Oklahoma that is heavily contami-
nated with metals from mining waste [Agency 
for Toxic Substances and Disease Registry 
(ATSDR) 2004]. It is part of the former 
Tri-State Mining District, which extended 
from Oklahoma through southeast Kansas 
and into southwest Missouri. In 1983, 
under the Comprehensive Environmental 
Response, Compensation, and Liability 
Act (“Superfund”) legislation (1980), the 
site was added to the National Priority List 
because of extensive metal contamination of 
surface water, groundwater, sediments, and 
soils (ATSDR 2004). Approximately 30,000 
people live in the area surrounding the site, 
including many residents of Native-American 
descent on allotted Indian land. Massive piles 
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Ba c k g r o u n d: Accumulating evidence has shown an increased risk of type 2 diabetes in general 
populations exposed to arsenic, but little is known about exposures during pregnancy and the asso-
ciation with gestational diabetes (GD). 
oBjectives: We studied 532 women living proximate to the Tar Creek Superfund Site to investi-
gate whether arsenic exposure is associated with impaired glucose tolerance during pregnancy.
Me t h o d s : Blood glucose was measured between 24 and 28 weeks gestation after a 1-hr oral glucose 
tolerance test (GTT) as part of routine prenatal care. Blood and hair were collected at delivery and 
analyzed for arsenic using inductively coupled plasma mass spectrometry with dynamic reaction cell. 
re s u l t s: Arsenic concentrations ranged from 0.2 to 24.1 µg/L (ppb) (mean ± SD, 1.7 ±1.5) and 
1.1 to 724.4 ng/g (ppb) (mean ± SD, 27.4 ± 61.6) in blood and hair, respectively. One-hour glucose 
levels ranged from 40 to 284 mg/dL (mean ± SD, 108.7 ± 29.5); impaired glucose tolerance was 
observed in 11.9% of women when using standard screening criterion (> 140 mg/dL). Adjusting 
for age, Native-American race, prepregnancy body mass index, Medicaid use, and marital status, 
women in the highest quartile of blood arsenic exposure had 2.8 higher odds of impaired GTT than 
women in the lowest quartile of exposure (95% confidence interval, 1.1–6.9) (p-trend = 0.008). 
co n c l u s i o n s: Among this population of pregnant women, arsenic exposure was associated with 
increased risk of impaired GTT at 24–28 weeks gestation and therefore may be associated with 
increased risk of GD.
key w o r d s : arsenic, gestational diabetes, impaired glucose tolerance, pregnancy, Superfund. 
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of mine tailings, known locally as “chat,” con-
tain elevated concentrations of lead, zinc, and 
other metals (Schaider et al. 2007). Many of 
the original chat piles have been partially exca-
vated and sold as fill for construction projects 
including roadways, playgrounds, residential 
driveways, and foundations of private homes 
(ATSDR 2004). In addition, at least 25% 
of drinking water samples in northeastern 
Oklahoma contain > 10 µg/L arsenic (Ryker 
2001; U.S. Geological Survey 2007). 
Study subjects. Subjects were participants 
in an ongoing prospective birth cohort study 
of biological markers of fetal and early child-
hood exposure to metals mixtures, mater-
nal psychosocial stress, and their impact on 
neurocognitive development. This research 
is being conducted in the area of the Tar 
Creek Superfund site as a collaborative effort 
between the Harvard School of Public Health 
(HSPH), the Local Environmental Action 
Demanded (L.E.A.D.) Agency (a community-
based nonprofit organization), and the Integris 
Baptist Regional Health Center, as part of 
the Center for Children’s Environmental 
Health and Disease Prevention Research at 
HSPH. The research protocol was approved 
by the Human Subjects Committees of 
Integris Health and Harvard School of Public 
Health and complied with all federal regula-
tions governing protection of human subjects. 
All participants received a detailed explana-
tion of the study before signing an approved 
written informed consent form. Interviewer-
administered questionnaires and medical 
records review were used to obtain informa-
tion about sociodemographic characteristics, 
potential environmental, occupational, and 
recreational sources of exposures, psychosocial 
stress, and details about the index pregnancy. 
Pregnant women were recruited during pre-
natal visits or upon admission for labor and 
delivery at the Integris Baptist Regional Health 
Center in Miami, Oklahoma, which is the 
only hospital in Ottawa County. To be eligible 
for participation in the cohort study, women 
must have met the following criteria: a) giving 
birth to a live-born infant at Integris hospi-
tal; b) intention to live within the study area 
(Ottawa County) for the next 2 years; c) not 
currently enrolled in the study with another 
child; and d) English language proficiency 
that would allow ability to read, understand, 
and participate in informed consent process 
in English. There were 2,312 births recorded 
at the hospital from 1 November 2002 to 15 
August 2008, and a total of 589 women were 
enrolled in the cohort during that same period. 
Because the birth cohort study was a continu-
ation of a smaller research endeavor, detailed 
data on enrollment and eligibility are not avail-
able for the entire study period. However, 
the exclusion criteria were designed to be as 
inclusive as possible, and the most common 
reasons for ineligibility were that women were 
already enrolled with another child or did not 
live (or were not intending to stay) in the area. 
Participants who were missing information on 
blood arsenic (n = 23) or blood glucose (n = 34) 
were excluded, leaving a total of 532 women 
included in this analysis. In a subset of these 
women with hair samples available (n = 179; 
34%), we conducted analyses using hair arsenic 
as a biomarker of exposure. The main reason for 
lack of an appropriate hair sample was that the 
participant had chemically treated hair.
Laboratory measurements. Maternal blood 
and hair samples were collected at delivery 
(± 12 hr) and analyzed for total arsenic concen-
tration at the HSPH Trace Metals Laboratory 
(Boston, MA). 
Hair was collected from the back of the 
head using high-grade stainless steel scissors 
to cut as close to the scalp as possible from 
all participants who had chemically untreated 
(“virgin”) hair (n = 179; 34%), which was 
requested to be free of any gels, oils, creams, 
sprays, or other styling products. Collection 
was done within a clean environment to avoid 
the introduction of external contaminants 
before, during, and after the collection process, 
and the following guidelines were maintained 
to ensure the collection of a metabolically rep-
resentative sample. Approximately 2 inches of 
virgin hair (representing the previous 5 months 
of exposure) was collected and placed directly 
into a small manila coin envelope provided by 
the laboratory and then sealed with the glue 
flap only. The weight required for the hair 
sample analysis is 0.125 g, which corresponds 
to about 50 strands of hair or the thickness of 
a pencil. Total hair arsenic concentration was 
meas  ured using previously published methods 
(Chen et al. 1999). The limit of detection for 
hair arsenic was 0.2 ng/g.
Whole blood was collected in trace ele-
ment–free tubes [BD Vacutainer royal blue 
top, venous blood collection tubes with 
K2EDTA #368381 (Becton Dickinson, 
Franklin Lakes, NJ)]. One milliliter of blood 
was transferred into a 15-mL plastic tube, 
digested with 2 mL concentrated HNO3 acid 
(Optima, Seastar Chemical Co., Pittsburgh, 
PA) for 24 hr, and then diluted to 10 mL with 
deionized water after adding 1 mL 30% hydro-
gen peroxide (Ultrex Ultrapure Reagents, J.T. 
Baker, Phillipsburg, NJ). Samples were fur-
ther diluted as needed. Acid-digested samples 
were then analyzed by inductively coupled 
plasma mass spectrometry with dynamic reac-
tion cell (Elan 6100; PerkinElmer, Norwalk, 
CT), using oxygen as the reaction gas. 
Concentration of arsenic was estimated using 
external calibration with indium as the inter-
nal standard. The limit of detection for blood 
arsenic was 0.2 µg/L.
Quality control measures for both 
blood and hair included analysis of the 
following: an initial calibration verification 
standard [National Institute of Standard 
and Technology (NIST; Gaithersburg, MD) 
standard reference material #1643e (trace ele-
ments in water)]; a solution of 1 ng/mL stan-
dard solution of arsenic (NIST traceable); 
continuous calibration standards; procedural 
blanks; and certified reference material GBW-
07601 (human hair; Institute of Geophysical 
and Geochemical Exploration, Langfang, 
China). Results were reported as the average 
of five replicate measurements per sample, 
and samples with relative standard deviation 
> 30% for the five replicates were flagged. 
Recovery of the analysis of quality control 
standard by this procedure is 90–110%, and 
coefficient of variation of the within-day anal-
ysis was ~ 0.05. The between-assay coefficient 
of variation for arsenic was 0.1. Samples with 
blood arsenic concentration < 0.2 µg/L (n = 4; 
0.7%), hair arsenic concentration < 0.2 ng/g 
(n = 4; 2%), or insufficient sample weight for 
analysis (n = 18; 10%) were reported as less 
than the limit of detection and not included 
in the analysis.
Maternal blood (plasma) glucose was meas-
ured at a prenatal visit between 24 and 28 weeks 
gestation after a 1-hr, 50-g oral glucose toler-
ance test (GTT) as part of routine prenatal care 
(ACOG 2001), and results were obtained from 
the medical record. All GTTs required that the 
patient be fasting after midnight the day before 
the administration of the test. Glucose was mea-
sured in plasma using the Beckman Coulter CX 
9 (Beckman Coulter, Inc. Fullerton, CA) at the 
Integris Baptist clinical laboratory.
Statistical analysis. Univariate and bivari-
ate summary statistics and distributional plots 
were examined for all variables. Spearman’s 
correlation between arsenic variables and 
blood glucose were examined. The arsenic 
exposure measurements were grouped into 
quartiles and entered into the models as 
dummy variables, with the lowest quartile 
used as the reference category. Impaired glu-
cose tolerance after the 1-hr, 50-g oral GTT 
was defined using standard screening crite-
ria as a blood glucose level of > 140 mg/dL 
(7.8 mmol/L), which provides sensitivity to 
identify approximately 80% of women with 
GD, and also using a more sensitive value of 
> 130 mg/dL (7.2 mmol/L), which identi-
fies approximately 90% of women with GD 
(ADA 2004). 
We used logistic regression to model pre-
diction of the probability of occurrence of 
impaired glucose tolerance in relation to arse-
nic exposure including the major risk factors 
for GD [age, race/ethnicity, prepregnancy 
body mass index (BMI)] as the main covari-
ates of interest. Covariates of interest were 
determined a priori based on biological con-
siderations, and other covariates (marital and 
insurance status) were added using statistical Arsenic and impaired glucose tolerance in pregnancy
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considerations if they were significant (p = 0.1) 
in bivariate models. Maternal age (centered) 
and centered age-squared were included in 
the models, because maternal age showed a 
U-shaped association in exploratory smooth 
plots. The linear test for trend [degrees of free-
dom (df) = 1] across exposure categories was 
conducted by assigning the quartiles of expo-
sure values of 0, 1, 2, 3 (ordinal variable) and 
specifying an appropriate linear combination 
vector (with a coefficient sum that equals 0) 
in a contrast statement. Linear models were 
also fitted using arsenic exposure as a con-
tinuous variable and presented for an IQR 
increase in exposure. To account for expo-
sure measurement error and thus decrease 
any downward bias in the effect estimates, 
models were weighted by the inverse of mea-
surement error (exposure) variance of the five 
laboratory replicates per sample. In a subset 
analysis, women reporting a previous history 
of diabetes (n = 20) or taking medications for 
diabetes (n = 2)—together labeled “history of 
diabetes”—were excluded from the analysis. 
To explore potential nonlinear associations 
between arsenic and blood glucose levels, we 
used generalized additive models with penal-
ized splines (df = 3) for the arsenic exposure 
variable weighted by the inverse of the vari-
ance of the exposure variable. All analyses were 
conducted using Statistical Analysis System 
(SAS version 9.1; SAS Institute Inc., Cary, 
NC) and R, version 2.2.0 (The R Foundation 
for Statistical Computing, Boston, MA).
Results
Maternal characteristics and their bivariate 
associations with impaired glucose tolerance 
are presented in Table 1. The mean (± SD) age 
of women in this cohort was 24.5 ± 5.4 years 
with 7% ≤ 18 years of age and almost 5% 
> 35 years of age. Approximately 74% gradu-
ated from high school, and most of the study 
cohort (81%) received public health insurance 
through SoonerCare, the Oklahoma State 
Medicaid program, which has inclusive eli-
gibility guidelines for pregnant women and 
children. More than one-third (37%) reported 
smoking cigarettes at some time during their 
pregnancy, and more than half the women 
(59%) were considered overweight or obese 
prior to pregnancy. Although most of the 
population was Caucasian (66%), women of 
Native American ancestry comprised almost 
24% of the cohort. 
Blood arsenic concentration ranged from 
0.2 to 24.1 µg/L [parts per billion (ppb)] 
(n = 532; mean 1.7 ± 1.5) and was signif-
icantly correlated with blood glucose level 
(Spearman’s rho = 0.1; p = 0.02). Hair arsenic 
concentration, available on a subset of partici-
pants, ranged from 1.1 to 724.4 ng/g (ppb) 
(n = 180; mean 27.4 ± 61.6) and was not sig-
nificantly correlated with blood glucose level 
(Spearman’s rho = 0.04; p = 0.6). Among 
the subset of women with both exposure bio-
markers available (n = 179), blood and hair 
arsenic levels were not significantly correlated 
with each other (Spearman’s rho = –0.13; 
p = 0.08). One-hour glucose levels ranged 
from 40 to 284 mg/dL (mean, 108.7 ± 29.5). 
Almost 12% of women participating had 
impaired GTTs (blood glucose > 140 mg/dL) 
at the 24- to 28-week prenatal visit. Using 
a more sensitive screening criterion (blood 
glucose > 130 mg/dL), > 20% had impaired 
GTT results. 
In bivariate analyses, maternal characteris-
tics significantly associated with higher blood 
arsenic levels were increasing maternal age, 
not having graduated from high school, use 
of public health assistance, married or living 
with partner, Native-American race/ethnicity, 
multiparity, higher prepregnancy weight and 
BMI, self-reported history of diabetes or high 
blood pressure, and having a cesarean-section 
Table 1. Distribution of maternal characteristics and their univariate associations with impaired glucose 
tolerancea at 28 weeks gestation, Ottawa County, Oklahoma, 2002–2008 (n = 532).
Characteristic  No. (%)b   OR (95% CI)
Age (years)
  14–18  39 (7.4)  0.54 (0.12–2.38)
  19–24  275 (52.0)  1.00 (referent)
  25–35  192 (36.2)  2.00 (1.14– 3.50)
  ≥ 36  25 (4.7)  1.91 (0.61–5.99)
Education
  < 12th grade   140 (26.4)  1.35 (0.76–2.38)
  ≥ 12th grade  391 (73.6)  1.00 (referent)
Insurance status
  State Medicaid  427 (80.7)  1.46 (0.68–3.08)
  Private  102 (19.3)  1.00 (referent)
Marital status
  Married or living with partner  326 (63.2)  2.41 (1.27–4.57)
  Never married/separated/divorced   190 (36.8)  1.00 (referent)
Race/ethnicity
  White  340 (66.2)  1.00 (referent)
  Native American  121 (23.5)  1.27 (0.70–2.32)
  Other  53 (10.3)  0.29 (0.07–1.22)
Parity (no.)
  1  212 (39.96)  1.00 (referent)
  2  170 (32.2)  1.42 (0.76–2.67)
  ≥ 3  148 (27.84)  1.34 (0.69–2.59)
Prepregnancy BMI (kg/m2)
  < 25  196 (41.4)  1.00 (referent)
  25–30  145 (30.7)  1.61 (0.76–3.42)
  ≥ 30  132 (27.9)  3.50 (1.76–6.95)
Weight gain during pregnancy (kg)
  < 10  169 (35.7)  1.00 (referent)
  10–15  133 (28.1)  0.83 (0.42–1.63)
  >15  171 (36.2)  0.67 (0.34–1.29)
Self-reported history of diabetes
  Yes  22 (4.2)  4.70 (1.89–11.70)
  No  507 (95.8)   1.00 (referent)
Self-reported history of high blood pressure
  Yes  34 (6.43)  2.03 (0.85–4.88)
  No  495 (93.6)  1.00 (referent)
Smoked during pregnancy 
  Yes  196 (37.0)  0.93 (0.53–1.61)
  No  333 (63.0)  1.00 (referent)
Prenatal vitamin use
  Yes  354 (66.7)  1.00 (referent)
  No  177 (33.3)  0.92 (0.52–1.62)
Blood arsenic (µg/L)
  Q1 (0.23–0.92)  133 (25)  1.00 (referent)
  Q2 (0.93–1.39)  133 (25)  1.24 (0.50–3.10)
  Q3 (1.40–2.08)  133 (25)  2.88 (1.28–6.49)
  Q4 (2.09–24.07)  133 (25)  2.44 (1.07–5.58)
Hair arsenic (ng/g)
  Q1 (1.10–8.81)  44 (25)  1.00 (referent)
  Q2 (8.93–13.11)  45 (25)  1.25 (0.31–5.00)
  Q3 (13.26–24.12)  45 (25)  2.16 (0.60–7.78)
  Q4 (24.22–724.41)  45 (25)  1.84 (0.50–6.80)
Q1–4, quartiles 1–4.
aImpaired glucose tolerance defined as 0: ≤ 140, 1: > 140 mg/dL. bData were missing for insurance status (n = 2), marital 
status (n = 15), race/ethnicity (n = 17), parity (n = 1), prepregnancy BMI (n = 58), weight gain during pregnancy (n = 58), self-
reported history of diabetes (n = 2) or high blood pressure (n = 2), smoked during pregnancy (n = 2), hair arsenic (n = 353). Ettinger et al.
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delivery, whereas lower blood arsenic concen-
tration was associated with taking prenatal 
vitamins (data not shown). 
In multivariate analyses (n = 456), adjust-
ing for age, Native-American race/ethnicity, 
prepregnancy BMI, Medicaid use, and marital 
status, women in the highest quartile of blood 
arsenic exposure had 2.79 higher odds of 
impaired GTT (> 140 mg/dL) than women 
in the lowest quartile of exposure [95% con-
fidence interval (CI), 1.13–6.87] (Table 2). 
There was a statistically significant trend in 
risk of impaired GTT by increasing quartile 
of exposure (p-trend = 0.008). Using the more 
sensitive criterion (> 130 mg/dL), women in 
the highest quartile of blood arsenic expo-
sure had 2.35 higher odds of impaired GTT 
(> 130 mg/dL) than women in the lowest 
quartile of exposure (95% CI, 1.18–4.69) 
(p-trend = 0.006). 
In models using arsenic exposure as a con-
tinuous variable and accounting for exposure 
measurement error (weighted by the inverse of 
exposure variance), an IQR increase in blood 
arsenic concentration was associated with 1.65 
times higher odds of impaired GTT (> 140 
mg/dL) (95% CI, 1.52–1.79) and with 1.73 
higher odds of impaired GTT (> 130 mg/dL) 
(95% CI, 1.61–1.87) (Table 2). Before the 
measurement error correction technique, an 
IQR increase in blood arsenic concentra-
tion was associated with 1.52 times higher 
odds of impaired GTT (> 140 mg/dL) (95% 
CI, 1.18–1.97) and with 1.42 higher odds 
of impaired GTT (> 130 mg/dL) (95% CI, 
1.13–1.77) (data not shown). 
Self-reported history of diabetes (n = 20) 
or taking medications for diabetes (n = 2) 
(“history of diabetes”) was a strong predictor 
of impaired glucose tolerance at the 24- to 
28-week prenatal visit in the bivariate anal-
ysis [odds ratio (OR) = 4.70; 95% CI, 
1.89–11.70] (Table 1). However, because we 
did not have physician-confirmed diagnoses 
and were relying on self-report, and because 
the occurrence of preexisting diabetes may also 
be causally related to arsenic exposure (and 
thus an intervening variable), we chose not 
to include this variable in the main models. 
When we restricted the models to include only 
women without self-reported history of diabe-
tes, not taking medications for diabetes, and 
with other covariates available (n = 439), the 
effect of arsenic exposure remained, as did the 
statistically significant trend. An interquartile 
range (IQR) increase in exposure (1.2 µg/L) 
was associated with 1.76 higher odds of 
impaired GTT (> 140 mg/dL) (95% CI, 
1.61–1.93) (p-trend = 0.04) and 1.83 higher 
odds of impaired GTT (> 130 mg/dL) (95% 
CI, 1.69–1.98) (p-trend = 0.02). 
We repeated these models in the subset of 
women with hair arsenic concentrations and 
the covariates of interest available (n = 149). 
Women in the highest quartile of hair arsenic 
exposure had 4.20 higher odds of impaired 
GTT (> 140 mg/dL) (95% CI, 0.74–23.86) 
than women in the lowest quartile of expo-
sure, although these results were not statisti-
cally significant (Table 3). Among subjects 
with no history of diabetes (n = 143), an 
IQR increase in exposure (15.3 ng/g) was 
associated with 2.70 higher odds of impaired 
GTT (> 140 mg/dL) (95% CI, 0.59–12.42) 
(p-trend = 0.11) and 1.55 higher odds of 
impaired GTT (> 130 mg/dL) (95% CI, 
0.44–5.44) (p-trend = 0.41). 
Figure 1 shows the adjusted dose–response 
relationship for the effect of blood arsenic 
(micrograms per liter) on blood glucose (mil-
ligrams per deciliter) from a generalized addi-
tive model. 
Discussion
Among this population of pregnant women 
with relatively low exposures, arsenic con-
centration was associated with impaired 
glucose tolerance during pregnancy and there-
fore may be associated with increased risk 
of GD. Women in the highest quartile of 
blood arsenic exposure had almost three times 
higher odds of impaired GTT than women 
in the lowest quartile of exposure, and there 
was a statistically significant trend in risk of 
impaired GTT by increasing quartile of expo-
sure. The prevalence of impaired glucose toler-
ance during pregnancy in this population was 
high (12–20%, depending on criteria used) 
and may be related to high prevalence of sev-
eral known risk factors for GD observed in 
this population. When we restricted the anal-
yses to women with no self-reported history 
of diabetes, the association of arsenic exposure 
Table 3. Risk of impaired glucose tolerance at 28 weeks gestation using two threshold criteria, by hair 
arsenic exposure.a 
    Excluding subjects with history 
  All subjects (n = 149)  of diabetes (n = 143)
Hair arsenic (ng/g)  ORb (95% CI)  ORc (95% CI)  ORb (95% CI)  ORc (95% CI)
Quartile
  Q1 (1.10–8.81)  1.00 (referent)  1.00 (referent)  1.00 (referent)  1.00 (referent)
  Q2 (8.93–13.11)  3.97 (0.62–25.37)  0.96 (0.27–3.38)  4.51 (0.36–56.55)  0.67 (0.17–2.75)
  Q3 (13.26–24.12)  5.77 (0.98–33.88)  2.44 (0.78–7.63)  13.24 (1.27–138.62)  2.48 (0.75–8.19)
  Q4 (24.22–724.41)  4.20 (0.74–23.86)  1.00 (0.31–3.29)  8.62 (0.87–85.20)  1.11 (0.32–3.78)
 p -trend  0.40  0.81  0.11  0.41
Continuousd
  IQR (15.3)  2.32 (0.52–10.39)  1.50 (0.41–5.49)  2.70 (0.59–12.42)  1.55 (0.44–5.44)
aAdjusted for maternal age (years), maternal age squared, prepregnancy BMI, Native-American race/ethnicity, Medicaid 
insurance, married or living with partner. bElevated glucose defined as 0: ≤ 140, 1: > 140 mg/dL. cElevated glucose defined 
as 0: ≤ 130, 1: > 130 mg/dL. dWeighted by the inverse of variance of exposure variable; one extreme outlier removed. 
Table 2. Risk of impaired glucose tolerance at 28 weeks gestation using two threshold criteria, by blood 
arsenic exposure.a
    Excluding subjects with history 
  All subjects (n = 456)  of diabetes (n = 439)
Blood arsenic (µg/L)  ORb (95% CI)  ORc (95% CI)  ORb (95% CI)  ORc (95% CI)
Quartile
  Q1 (0.23–0.92)  1.00 (referent)  1.00 (referent)  1.00 (referent)  1.00 (referent)
  Q2 (0.93–1.39)  1.02 (0.39–2.69)  1.03 (0.50–2.10)  1.07 (0.39–2.98)  1.00 (0.48–2.10)
  Q3 (1.40–2.08)  2.65 (1.12–6.36)  2.21 (1.14–4.29)  2.83 (1.14–7.02)  2.23 (1.14–4.38)
  Q4 (2.09–24.07)  2.79 (1.13–6.87)  2.35 (1.18–4.69)  2.46 (0.91–6.62)  2.08 (1.01–4.27)
 p -trend  0.008  0.006  0.04  0.02
Continuousd
  IQR (1.2)  1.65 (1.52–1.79)  1.73 (1.61–1.87)  1.69 (1.54–1.84)  1.79 (1.65–1.93)
aAdjusted for maternal age (years), maternal age squared, prepregnancy BMI, Native-American race/ethnicity, Medicaid 
insurance, married or living with partner. bElevated glucose defined as 0: < 140, 1: > 140 mg/dL. cElevated glucose defined 
as 0: < 130, 1: > 130 mg/dL. dWeighted by the inverse of variance of exposure variable; one extreme outlier removed.
Figure 1. Adjusted dose–response relationship for the 
effect of blood arsenic (µg/L) on blood glucose (mg/
dL) from a generalized additive model with penalized 
splines (df = 3, p = 0.01) adjusted for age (centered), 
centered age-squared, prepregnancy BMI, Native-
American race/ethnicity, use of Medicaid insurance, 
and married or living with partner; weighted by the 
inverse of the variance of exposure variable (n = 
455). Dashed lines represent 95% CIs. Vertical bars 
along the abscissa mark the observed values of 
blood arsenic for individual subjects.
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on impaired glucose tolerance remained. The 
effect of the measurement error correction 
technique applied was, as expected, to reduce 
the downward bias in the effect estimates due 
to nondifferential misclassification of exposure 
by the laboratory. 
Environmental exposures may result 
in abnormal glucose metabolism, which in 
turn increases the risk of developing diabe-
tes, through several plausible mechanisms 
(Longnecker and Daniels 2001). Arsenic is 
a known endocrine disruptor (Tseng 2004) 
and may disrupt the glucocorticoid recep-
tor (Kaltreider et al. 2001), which regulates a 
wide range of biological processes in humans, 
including insulin sensitivity. It is also possible 
that some aspect of having diabetes or predia-
betes alters arsenic metabolism in such as way 
as to cause higher levels in the body. However, 
experimental evidence suggests that oxidative 
stress and insulin resistance can be induced by 
arsenic, suggesting a biological plausibility to 
arsenic-induced diabetes (Tseng et al. 2004). 
In a recent analyses of NHANES (National 
Health and Nutrition Examination Survey) 
data, average urinary total arsenic concentra-
tions were 8.30 µg/L (95% CI, 7.19–9.57) 
(Caldwell et al. 2008). Using data from the 
same nationally representative cross-sectional 
survey of the U.S. population, Navas-Acien 
and colleagues (2008) found that participants 
with type 2 diabetes had a 26% higher level of 
total arsenic (95% CI, 2.0–56.0) and the OR 
for type 2 diabetes comparing participants at 
the 80th versus the 20th percentiles was 3.58 
for the level of urinary total arsenic (95% CI, 
1.18–10.83). One previous study has shown 
an association with environmental exposures 
(agricultural pesticides) and increased risk of 
GD among wives of licensed pesticide applica-
tors (Saldana et al. 2007); however, that study 
relied on self-report of GD and pesticide usage. 
In this study, we used sensitive labora-
tory biomarkers of both the exposure (arse-
nic) and outcome (plasma glucose). Levels of 
total arsenic exposure (measured in mater-
nal blood and hair) in our study were higher 
than reported background levels of arsenic 
in unexposed individuals (ATSDR 2007). 
Exposure at hazardous waste sites may occur 
by a variety of pathways, including inhalation 
of dusts in air, ingestion of contaminated soil 
or water, or through the food chain. We do 
not have data on speciated arsenic available to 
differentiate between inorganic and organic 
arsenic exposure. However, these results taken 
together suggest that if our findings are con-
firmed, a significant portion of U.S. women 
of childbearing age may be at risk for GD due 
to environmental exposures such as arsenic.
One limitation of our study was that we 
used blood collected at the time of delivery as a 
biomarker of arsenic exposure, which was mea-
sured after the outcome measurement (blood 
glucose). Because arsenic binds to the sulfhy-
dryl groups in keratin, the primary component 
in hair and nails, this is where the highest levels 
of arsenic tend to be found (Liu et al. 2008). 
Therefore, studies of chronic arsenic exposure 
often use hair or nails as biomarkers of cumula-
tive exposure. Although nails or hair may best 
represent cumulative exposure, keratin-bound 
arsenic is isolated from the body’s further met-
abolic processes and may be less biologically 
active than blood arsenic. Because of these dif-
ferences in biomarkers of arsenic exposure, we 
used hair, in a subset of women with samples 
available, to provide estimates of longer-term 
exposures, with every 1 cm of hair represent-
ing each month of prior exposure (Kurttio 
et al. 1998). We found similar results, though 
not statistically significant, to those from our 
analyses using blood arsenic. We believe this is 
because with chronic exposures, blood arsenic 
likely reaches a steady-state concentration and 
therefore may better reflect an individual’s total 
internal arsenic dose (Hall et al. 2006). 
In our study, in the subset of women with 
both samples available, blood and hair arsenic 
concentrations were not correlated. However, 
blood arsenic concentration has previously 
been found to correlate both with other bio-
logical matrices and with environmental 
sources of arsenic. In a Bengali population 
with much higher levels of exposure, blood 
arsenic levels were highly correlated with 
  creatinine-adjusted urinary concentrations 
(r = 0.85) and with drinking-water arsenic 
concentration (r = 0.75) (Hall et al. 2006). In 
addition, blood arsenic also correlated with 
arsenic metabolites including methylated 
forms, which may represent the most toxic 
arsenic species (Hall et al. 2007). 
Another limitation of our study is that we 
used the results of GTTs performed as part 
of routine prenatal care and not conducted as 
part of a structured research protocol. We used 
blood glucose measured after a fasting, 50-g 
oral glucose challenge test, which is the recom-
mended standard of care (ACOG 2001), to 
identify women with impaired glucose toler-
ance who should go on to receive further test-
ing to diagnose GD. We found similar results 
when using two threshold criteria for defining 
impaired glucose tolerance (> 140 and > 130 
mg/dL). In addition, all of our tests were con-
ducted and analyzed at one clinical laboratory 
facility and conducted independently of arse-
nic concentration, making any misclassifica-
tion of the outcome likely nondifferential with 
respect to exposure and thus biasing our results 
toward the null hypothesis of no effect. 
Our results likely represent more than a 
potential causal association between arsenic 
and GD but may also provide clues to long-
observed health disparities that have been 
resistant to public health interventions. It is 
well recognized that there are many diseases 
and disorders that disproportionately affect the 
health of racial and ethnic minority populations 
in the United States. Women from minority 
groups, especially Native-American women, 
are much more likely to have type 2 diabe-
tes during their childbearing years (National 
Institute of Diabetes and Digestive and Kidney 
Diseases 2006, 2008). In addition, these groups 
may be disproportionately affected by expo-
sure to environmental contaminants due to 
socioeconomic conditions and cultural prac-
tices that use locally grown plants and animals 
and may differentially increase exposure when 
environmental contamination occurs (Harris 
and Harper 1997). We found Native-American 
race to be a predictor, although not statisti-
cally significant, of impaired glucose tolerance 
in pregnancy. Also, Ottawa County is an eco-
nomically deprived area with a poverty rate 
higher than the Oklahoma state and national 
averages (Oklahoma County Health Care 
Authority 2005). Most of our cohort received 
public health insurance through SoonerCare, 
the Oklahoma State Medicaid medical ben-
efits program, which has more lenient eligibility 
guidelines than federal standards, allowing more 
pregnant women and children to access health 
care. These findings highlight the need to iden-
tify and ameliorate racial, socioeconomic, and 
environmental disparities that may be adversely 
affecting the health of the particularly vulner-
able populations such as pregnant women and 
children (Silbergeld and Patrick 2005). 
In summary, GD is a major potential com-
plication of pregnancy associated with negative 
health effects for both the mother and infant. 
Understanding the effects of environmental 
exposures on impaired glucose tolerance during 
pregnancy may have substantial public health 
importance beyond the direct effects on GD. 
Studies are needed to investigate environmen-
tal or behavioral factors that may contribute to 
risk for development and progression of diabe-
tes, obesity, and its complications. Such studies 
should incorporate culturally specific lifestyle 
factors into treatment and prevention strategies 
to reduce risk across racial, ethnic, and socio-
economic groups. Future research in this area 
will be important for understanding whether 
different pathophysiologic mechanisms or risk 
factors are responsible for increased obesity and 
diabetes risk, especially in children. In addi-
tion, better understanding of modifiable risk 
factors for GD such as diet and activity pat-
terns related to environmental exposures may 
lead to efforts at primary prevention.
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